A Phase II, Randomized Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BGM0504 Compared to Tirzepatide in Adults Who Have Obesity
Latest Information Update: 08 Apr 2025
At a glance
- Drugs BGM 0504 (Primary) ; Tirzepatide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors BrightGene Bio-medical technology
- 08 Apr 2025 New trial record